There’s a different equity story being told by sentiment: Reata Pharmaceuticals Inc. (RETA).

In the latest session, Reata Pharmaceuticals Inc. (NASDAQ: RETA) closed at $84.36 down -0.53% from its previous closing price of $84.81. In other words, the price has decreased by -$0.45 from its previous closing price. On the day, 693550 shares were traded. RETA stock price reached its highest trading level at $87.78 during the session, while it also had its lowest trading level at $82.63.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".



For a deeper understanding of Reata Pharmaceuticals Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.70 and its Current Ratio is at 6.70.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Guggenheim on October 19, 2022, initiated with a Buy rating and assigned the stock a target price of $75.

SVB Leerink Downgraded its Outperform to Mkt Perform on December 09, 2021, while the target price for the stock was maintained at $35.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 10 when Ruff Shamim sold 5,740 shares for $83.73 per share. The transaction valued at 480,610 led to the insider holds 5,223 shares of the business.

Bir Dawn Carter sold 42,042 shares of RETA for $3,582,002 on Mar 07. The Chief Commercial Officer now owns 41,513 shares after completing the transaction at $85.20 per share. On Mar 07, another insider, Loewen Andrea, who serves as the SVP, Global Regulatory Affairs of the company, sold 19,036 shares for $83.43 each. As a result, the insider received 1,588,137 and left with 38,757 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 1436.04.

Stock Price History:

Over the past 52 weeks, RETA has reached a high of $95.00, while it has fallen to a 52-week low of $18.47. The 50-Day Moving Average of the stock is 50.58, while the 200-Day Moving Average is calculated to be 35.92.

Shares Statistics:

For the past three months, RETA has traded an average of 1.47M shares per day and 3.11M over the past ten days. A total of 36.65M shares are outstanding, with a floating share count of 30.57M. Insiders hold about 3.73% of the company’s shares, while institutions hold 89.30% stake in the company. Shares short for RETA as of Jan 12, 2023 were 8.14M with a Short Ratio of 8.36M, compared to 7.32M on Dec 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 22.20% and a Short% of Float of 39.71%.

Earnings Estimates

There are 8 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$2.21 for the current quarter, with a high estimate of -$2.02 and a low estimate of -$2.35, while EPS last year was -$2.35. The consensus estimate for the next quarter is -$2.28, with high estimates of -$2.01 and low estimates of -$2.56.

Analysts are recommending an EPS of between -$8.23 and -$8.56 for the fiscal current year, implying an average EPS of -$8.41. EPS for the following year is -$8.43, with 8 analysts recommending between -$6.13 and -$10.34.

Revenue Estimates

A total of 10 analysts have provided revenue estimates for RETA’s current fiscal year. The highest revenue estimate was $4.22M, while the lowest revenue estimate was $2.2M, resulting in an average revenue estimate of $2.63M. In the same quarter a year ago, actual revenue was $11.49M, down -77.10% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $26.24M in the next fiscal year. The high estimate is $38.81M and the low estimate is $9.22M. The average revenue growth estimate for next year is up 897.70% from the average revenue estimate for this year.